Stocks may move to the upside in early trading on Friday following the moderate weakness seen in the previous session. The major index futures are currently pointing to a modestly higher open for the markets, with the Dow futures up by 22 points.
Consumer goods giant Procter & Gamble Co. on Friday reported a profit for the second quarter that more than doubled from last year on a one-time gain and higher margins, while sales edged lower. Both revenue and core earnings per share for the quarter beat analysts' estimates.
General Electric Company (GE) reported that its fourth-quarter Industrial operating plus Verticals EPS, a non-GAAP measure, decreased to $0.46 from $0.52 last year. Industrial operating plus Verticals earnings excluding gains & restructuring was $0.50 compared to $0.47. On average, 17 analysts polled...
As Donald Trump's inauguration is the major focus of the day, the futures are up, indicating a higher opening for the Wall Street. On a very lean day, a few Fed speeches and the rig count data may drive trade. Asian shares
As of 6:25 am ET, the Dow futures are climbing 11 points, the S&P 500 futures are advancing 5.75 points and the Nasdaq 100 futures are progressing 14.75 points.
U.K. retail sales declined at the fastest pace in more than four years in December as consumers minimized their spending amid rising inflation. Retail sales volume including auto fuel fell 1.9 percent from November, when it dropped by a marginal 0.1 percent, the Office for National Statistics said Friday.
European stocks were little changed on Friday as disappointing U.K. retail sales data dampened optimism on the British economy and investors looked for more details on U.S. President-elect Donald Trump's policies.
Trump will swear in as the President of the United States of America today, with market...
Shares of Synergy Pharmaceuticals Inc. (SGYP) were up over 5% in extended trading on Thursday, following FDA approval of TRULANCE for the treatment of adults with chronic idiopathic constipation.
European stocks are seen opening mixed on Friday as investors digest dovish comments from ECB President Mario Draghi and look forward to U.S. President-elect Donald Trump's inaugural address later in the day.
Crude oil futures extended overnight gains, brushing off a surprise build in U.S. crude...
Goldman Sachs downgraded the rating of retailer Target Corp. Thursday to sell from neutral over concerns about its increasing competition with e-commerce giant Amazon.com Inc. Target's price target was reduced to $67 from $77. It is expected that the retailer's efforts to compete with Amazon will result in sluggish sales and profits.
Catabasis' phase II trial of Edasalonexent in boys affected by Duchenne muscular dystrophy is ongoing, and top-line results are anticipated in the first half of Q1 2017.
International Business Machines Corp. (IBM) Thursday reported an increase in profit for the fourth quarter, that also trumped Wall Street estimates.
Armonk, New York-based IBM's fourth-quarter profit rose to $4.50 billion or $4.72 per share from $4.46 billion or $4.59 per share last year.
American Express Co. (AXP) Thursday reported a drop in fourth-quarter profit, as revenues declined 4 percent due to absence of Costco portfolio while provisions for bad loans and marketing costs increased. Earnings fell short of Wall Street estimates, while revenues trumped expectations.
After initially showing a lack of direction, stocks moved moderately lower over the course of the trading session on Thursday. The Dow closed lower for the fifth consecutive session, falling to its lowest closing level in over a month.
Pharmaceutical company Kaleo Thursday announced that Auvi-Q, the rival for EpiPen, will be available by prescription starting February 14 for $360.
Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
Auvi-Q is a epinephrine injection used to treat life-threatening allergic...
During a hearing on his nomination to run the Energy Department on Thursday, former Texas Governor Rick Perry expressed regret for previously recommending the department's elimination.
Testifying before the Senate Committee on Energy and Natural Resources, Perry said he had learned a great deal about...